Acumen Pharmaceuticals (ABOS) Assets Average (2021 - 2026)
Acumen Pharmaceuticals (ABOS) posted Assets Average of $128.2 million for Q1 2026, down 3.24% sequentially from $132.5 million in Q4 2025, and down 42.17% YoY from $221.7 million in Q1 2025.
Acumen Pharmaceuticals (ABOS) Assets Average (2021 - 2026) Analysis & Trends
Acumen Pharmaceuticals has reported Assets Average for 6 years, with the latest figure at $128.2 million in Q1 2026.
- Quarterly Assets Average fell 42.17% year-over-year to $128.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $128.2 million (down 42.17% YoY) and the FY2025 annual result came in at $180.9 million, down 34.11% from the prior year.
- Assets Average fell to $128.2 million in Q1 2026 per ABOS's latest filing, from $132.5 million in the prior quarter.
- Over five years, Assets Average peaked at $305.5 million in Q1 2024 and troughed at $128.2 million in Q1 2026.
- A 5-year average of $218.4 million and a median of $215.9 million in 2022 frame the typical range for Assets Average.
- The sharpest annual moves came in 2024 and 2025: Assets Average jumped 61.49% in 2024, then sank 47.61% in 2025.
- Over 5 years, Assets Average stood at $199.9 million in 2022, then jumped by 49.18% to $298.2 million in 2023, then retreated by 15.18% to $253.0 million in 2024, then slumped by 47.61% to $132.5 million in 2025, then slipped by 3.24% to $128.2 million in 2026.
- According to Business Quant data, Assets Average over the past three periods registered $128.2 million, $132.5 million, and $157.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 5.34 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 2.09 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.82 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 25.27 Bn |
| 10 | Acumen Pharmaceuticals | 229.03 Mn | 229.03 Mn | - | 124.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 124.82 Mn |
| Mar 31, 2026 | 128.23 Mn |
| Dec 31, 2025 | 132.53 Mn |
| Sep 30, 2025 | 157.06 Mn |
| Jun 30, 2025 | 188.19 Mn |
| Mar 31, 2025 | 221.74 Mn |
| Dec 31, 2024 | 252.98 Mn |
| Sep 30, 2024 | 277.94 Mn |
| Jun 30, 2024 | 294.94 Mn |
| Mar 31, 2024 | 305.55 Mn |
| Dec 31, 2023 | 298.25 Mn |
| Sep 30, 2023 | 231.89 Mn |
| Jun 30, 2023 | 182.63 Mn |
| Mar 31, 2023 | 192.23 Mn |
| Dec 31, 2022 | 199.93 Mn |
| Sep 30, 2022 | 207.47 Mn |
| Jun 30, 2022 | 215.88 Mn |
| Mar 31, 2022 | 225.21 Mn |
| Dec 31, 2021 | 232.59 Mn |
| Sep 30, 2021 | 153.90 Mn |